SNT-5382 is under clinical development by Syntara and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNT-5382’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNT-5382 overview
SNT-5382 is under development for the treatment of idiopathic pulmonary fibrosis, chronic kidney disease, non-alcoholic steatohepatitis. The drug candidate is administered orally. It targets lysyl oxidase-like protein 2 (LOXL2).
It was also under development for myocardial fibrosis, kidney fibrosis and liver fibrosis.
Syntara overview
Syntara, formerly Pharmaxis, is a clinical-stage drug development company. It develops drugs for inflammatory, fibrotic and selected cancer indications diseases. The company product pipeline comprises of PXS-5505, PXS-5382, PXS-6302, PXS-4728, PXS-4699 and PXS-5370. Syntara therapeutic areas include myelofibrosis, liver and pancreatic cancer, pulmonary fibrosis, anti-fibrotic, IPF, CKD and NASH, anti-scarring, burns, established scars, isolated rapid eye movement sleep behavior disorder (IRBD), Parkinson’s disease, anti-inflammatory and multiple indications. It sells its products under the brands Bronchitol and Aridol. Syntara is headquartered in Sydney, French Forest, Australia.
For a complete picture of SNT-5382’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
